therapeutic 1,141 words KG: ent-gene-679b721f
Contents

GPR37 Modulator Therapy for Parkinson's Disease

🔬 Protein Info
Gene Symbolent-gene-679b721f
Mendelian mutationsGPR37 loss-of-function mutations cause autosomal recessive juvenile parkinsonism with features resembling PARK2 (PARKIN) mutations
Association with sporadic PDGPR37 polymorphisms are associated with altered PD risk in genome-wide association studies[@liu2021]
Co-localization with PARKINGPR37 physically interacts with PARKIN, the E3 ubiquitin ligase mutated in the second most common form of familial PD
Orphan receptorDespite structural similarity to endothelin receptors, no definitive endogenous ligand has been established
Constitutively activeExhibits baseline signaling activity independent of ligand
G protein couplingPrimarily Gi/Go-coupled, inhibiting adenylate cyclase
β-arrestin pathwaySignals through β-arrestin-dependent mechanisms independent of G proteins
ER retentionMutant GPR37 is retained in the ER, causing cellular stress
KG Connections2 knowledge graph edges
DatabasesGeneCardsUniProtNCBI GeneHPASTRING

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

Wikipedia

Related Hypotheses (35)

Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
R-Loop Resolution Enhancement Therapy
Score: 0.68
Arginine Methylation Enhancement Therapy
Score: 0.65
Glial Glycocalyx Remodeling Therapy
Score: 0.65
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.65
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
Temporal Decoupling via Circadian Clock Reset
Score: 0.54
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.48
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.47
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
APOE Isoform Conversion Therapy
Score: 0.72
Cholesterol-CRISPR Convergence Therapy for Neurodegeneration
Score: 0.62
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.55
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.55
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47
← Prevpg 2/2

Related Analyses (30)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · completed
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · completed
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived

Related Experiments (30)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40

Knowledge Graph (2 edges)

ent-gene-679b721f data_in benchmark_ot_ad_answer_key:GPR37
benchmark_ot_ad_answer_key:GPR37 data_in ent-gene-679b721f

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.